Search alternatives:
points decrease » point decrease (Expand Search), point increase (Expand Search)
mean decrease » a decrease (Expand Search)
mg decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
_ decrease » _ decreased (Expand Search)
3 points » _ points (Expand Search), _ point (Expand Search), 5 point (Expand Search)
50 mg » 10 mg (Expand Search)
points decrease » point decrease (Expand Search), point increase (Expand Search)
mean decrease » a decrease (Expand Search)
mg decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
_ decrease » _ decreased (Expand Search)
3 points » _ points (Expand Search), _ point (Expand Search), 5 point (Expand Search)
50 mg » 10 mg (Expand Search)
-
1
-
2
-
3
-
4
Capzb2 coimmunoprecipitates with βIII-tubulin in brain lysates and decreases tubulin polymerization in vitro.
Published 2009“…<p>(A) In order to avoid overlap of the heavy chain signal (∼50 kDa) with the βIII-tubulin signal (∼55 kDa) in the immunoprecipitation using the Capzb2 monoclonal antibody (mAb), the antibody was coupled to the protein G/A beads through cross-linking. βIII-tubulin and Capzb2 signals were each detected following immunoprecipitation from brain lysate with both βIII-tubulin rabbit antibody (rAb)-coupled beads and Capzb2 mAb-coupled beads. …”
-
5
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
6
-
7
-
8
-
9
-
10
-
11
Mean percentage changes (95% CI) in total testosterone, SHBG and free testosterone (mITT analysis).
Published 2024Subjects: -
12
Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.
Published 2016“…<p>Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.…”
-
13
-
14
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
Published 2025“…<b>(B)</b> A significant decrease in the proliferative clonal capacity of U251MG colonies was observed with 50ΜM and 100ΜM SHG-44 treatment. …”
-
15
-
16
-
17
-
18
-
19
-
20